Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
PZ HTL SA

Virtual Screening Identifies New Low Molecular Weight Anticancer Drug Candidates

By BiotechDaily International staff writers
Posted on 21 Feb 2013
Computer modeling and high throughput molecular screening were used to identify low molecular weight compounds capable of blocking the activity of procancerous signaling molecules called G-protein mediated Rho guanine nucleotide exchange factors (GEFs).

GEFs have been implicated in several human diseases including cancer, but finding suitable drugs to block their activity has proven difficult due to a lack of distinctive formational features in the three-dimensional structure of these molecules. Investigators at Cincinnati Children's Hospital Medical Center (OH, USA) have approached this problem from a new direction.

They reported in the February 4, 2013, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) that they had virtually screened chemicals that fit into a surface groove of the DH-PH domain of LARG (leukemia-associated Rho guanine nucleotide exchange factor), a G-protein-regulated Rho GEF involved in RhoA activation, and had followed up the virtual tests with validations in biochemical assays. This methodology allowed them to identify a class of chemical inhibitors represented by Y16 that was active in specifically inhibiting LARG binding to RhoA.

RhoA (Ras homolog gene family, member A) is a small GTPase protein known to regulate the actin cytoskeleton in the formation of stress fibers. This protein is essential for the signaling function of the Rho GTPase complex. Previous studies have shown that in breast cancer increased RhoA activity stimulated cancer cell invasiveness and spreading, while RhoA deficiency suppressed cancer growth and progression. In addition to its role in breast cancer, imbalance in Rho GTPase activity has been implicated in other human diseases, including various cancers and neurological disorders.

The suppressive effect of Y16 was significantly amplified by using the compound together with Rhosin/G04, a drug previously shown to target RhoA. The combination of Y16 and Rhosin/G04 did not interfere with other cellular signaling functions.

"We are using the findings from this study to refine our compounds and test them on mouse models of acute myeloid leukemia and certain metastatic tumors—especially breast cancer, where the target pathway of this lead inhibitor is hyperactive," said senior author Dr. Yi Zheng, professor of pediatrics at Cincinnati Children's Hospital Medical Center.

Related Links:
Cincinnati Children's Hospital Medical Center


Channels

Genomics/Proteomics

view channel
Image: Biopsy of small bowel showing celiac disease manifested by blunting of villi, crypt hyperplasia, and lymphocyte infiltration of crypts (Photo courtesy of Wikimedia Commons).

Reduced Elafin Levels Associated with Celiac Disease Bowel Inflammation

Levels of the enzyme elafin, an endogenous serine protease inhibitor, were lower in the small intestinal epithelium of patients with active celiac disease (CD) as compared to similar tissue from control patients.... Read more

Drug Discovery

view channel

Retinoic Acid Prevents Precancerous Breast Cells from Progressing to Full-Blown Cancer

Retinoic acid, a derivative of vitamin A, was found to prevent pre-cancerous breast cells from progressing to full-blown cancer but did not have any effect on breast tumor cells. Investigators at Thomas Jefferson University (Philadelphia, PA, USA) worked with a novel breast cancer model that had been developed by treating... Read more

Biochemistry

view channel

Mitochondrial Cause of Aging Can Be Reversed

Researchers have found a cause of aging in lab animals that can be reversed, possibly providing an avenue for new treatments for age-related diseases including type 2 diabetes, cancer, muscle wasting, and inflammatory diseases. The researchers plan to begin human trials late 2014. The study, which was published December... Read more

Therapeutics

view channel

Cytokine Identified That Causes Mucositis in Cancer Therapy Patients

The action of the cytokine interleukin 1-beta (IL-1beta) has been found to underlie the onset of mucositis, a common, severe side effect of chemotherapy and irradiation of cancer patients. Mucositis occurs as a result of cell death in reaction to chemo- or radiotherapy. The mucosal lining of the mouth becomes thin, may... Read more

Business

view channel

Analytical Sciences Trade Fair Declared a Rousing Success

Organizers of this year's 24th "analytica" biosciences trade fair have reported significant increases in both the number of visitors and exhibitors compared to the 2012 event. The analytica trade fair for laboratory technology, analysis, and biotechnology has been held at the Munich (Germany) Trade Fair Center every... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.